Shanghai Henlius Biotech, backed by Chinese conglomerate Fosun International (0656.HK), launched on Wednesday its Hong Kong IPO of up to $477 million, a term-sheet showed, the first sizeable float to test market sentiment amid the city’s political unrest.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
